Curriculum Vitae

Matteo Luca Vecellio

Address: 1b, New Cross Road, OX3 8LP, Oxford (UK);

Mobile: (+44)7454794358

e-mail: teovec82@gmail.com (personal)
matteo.vecellio@ndorms.ox.ac.uk (work)

Nationality: Italian

Date of birth: October 21st , 1982

Sex: Male

Work Experiences

June 2017 - current
Arthritis Research UK Career Development Fellow at the Botnar Research Centre, NDORMS – Institute of Musculoskeletal Sciences, University of Oxford

June 2013 – May 2017
Post Doc at the Botnar Research Centre, NDORMS – Institute of Musculoskeletal Sciences Professor Wordsworth Lab, University of Oxford

June 2012 - May 2013
Post Doc at the Division of Cardiovascular Epigenetics – Department of Cardiology Klinikum, Goethe University with a Loewe CGT (Exzellente Forschung fur Hessens Zukunft) fellowship. Prof. Gaetano's Lab

From October 2008 until May 2012

Ph.D. Student within the Ph.D. Program in Translational and Molecular Medicine (DIMET – University of Milan Bicocca) - working at the Vascular Biology and Regenerative Medicine Lab, Centro Cardiologico Monzino- Milan
Prof. Gaetano, Capogrossi and Pompilio Lab – Mentor: Dr. Avitabile

From March 2008 until September 2008
Fellow (Dulbecco Telethon Institute)
Molecular Genetics of Mental Retardation Lab, Dibit – HSR, Milan
Prof D'Adamo lab

Education

October 2008 - January 2012
Ph.D. in Translational and Molecular Medicine (DIMET – University of Milan – Bicocca) (May, 2012); Grade: **very good (A)**

Thesis work was carried out in Vascular Biology and Regenerative Medicine Lab, Centro Cardiologico Monzino- IRCCS- Milan
ISCED 6

November 2005 - March 2008

MSc degree in Medical Biotechnology – Curriculum Experimental Medicine Grade: **110/110 cum laude** (March 5th , 2008) University of Milan - Bicocca

Thesis work was carried out in the Lab of Molecular Genetics of Mental Retardation
ISCED 5

Awards/Grants

1. "Post-Doctoral Fellowship-year 2014" **Umberto Veronesi Foundation (Italy)**
2. "Post-Doctoral Fellowship-year 2015" **Umberto Veronesi Foundation (Italy)**
3. "EULAR Abstract Awards 2016 in Basic Science" – **EULAR 2016 Congress (London)**
4. **"Fondation de France"** Post-Doctoral Grant 2016
5. **"Arthritis Research UK Career Development Award" (5 years 2017-2021)**
6. "EULAR Travel Bursary 2018" – **EULAR 2018 Congress (Amsterdam)**
7. **"Arthritis Research UK Travel support" – SpA Meeting 2018 (Ghent)**

Speaker & **Poster presenter** at several International Congresses including:

1. Oral presentation, ABCD meeting on Stem Cells and Regenerative Medicine, Parma, Italy, April 9-10, 2010
2. Oral presentation at the AHA Scientific Sessions, Orlando, Florida, USA, November 12-16, 2011

3. Poster presentation at DZHK Epigenetic Meeting "Epigenetics & system biology in cardiovascular diseases", Berlin, April 22, 2013
4. Invited speaker at IGAS, International Genetics of Ankylosing Spondylitis Consortium (IGAS), Shanghai, China, April 11-13, 2014
5. 9th International Congress on Spondyloarthropathies, Gent, Belgium, October 23-25, 2014 (poster)
6. Oral presentation, 3rd International Conference and Exhibition on Cell & Gene Therapy, Embassy Suites Las Vegas, USA, October 27-29, 2014
7. Poster presentation at Keystone Symposia on Epigenomics and DNA methylation, Keystone, Colorado, USA, March 29-April 3, 2015 (poster)
8. Oral presentation, EULAR 2016 congress, London, United Kingdom, June 8-11, 2016
9. Invited speaker at IGAS, International Genetics of Ankylosing Spondylitis Consortium (IGAS), Palermo, Italy, October 12-14, 2017
10. Oral presentation, EULAR 2018 congress, Amsterdam, The Netherlands, June 13-16, 2018

Publications list

1. Novel targeted approaches to drug development in ankylosing spondylitis: lessons from RUNX3 and T-bet
(In press *Front Immunol*)
Vecellio M*, Cohen CJ, Roberts AR, Wordsworth BP and Tony Kenna
*corresponding author

2. Quantifying the genetic risk for the development of axial SpA - could this become a diagnostic tool?
Wordsworth BP, Cohen CJ and **Vecellio M**
Curr Opin Rheumatol 2018 Apr 26. doi: 10.1097/BOR.0000000000000517

3. Evidence for a second ankylosing spondylitis associated RUNX3 regulatory polymorphism
Vecellio M, Cortes A, Roberts AR, Ellis J, Cohen CJ, Knight JC, Brown MA, Bowness P and Wordsworth BP
RMD Open 2018 Feb 8;4(1):e000628. doi: 10.1136/rmdopen-2017-000628)

4. The severity of ankylosing spondylitis and responses to anti-tumour necrosis factor biologics are not influenced by the TNF receptor polymorphism incriminated in multiple sclerosis
Watts L, Karaderi T, Roberts AR, Appleton L, Wordsworth T, Cohen C, Wordsworth BP and **Vecellio M***
Genes Immun 2018 DOI : 10.1038/s41435-018-0017-0
*corresponding author

5. Investigation of a possible extended risk haplotype in the IL23R region associated with ankylosing spondylitis.
Roberts AR, **Vecellio M**, Cortes A, Knight JC, Cohen CJ, Wordsworth BP.
Genes Immun. 2017 Mar;18(2):105-108.

6. Reply to Reeves et al.: No evidence for rare ERAP1 haplotypes and haplotype combinations in ankylosing spondylitis.
Wordsworth BP, **Vecellio M**, Roberts AR.
Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):E1577.

7. ERAP1 association with ankylosing spondylitis is attributable to common genotypes rather than rare haplotype combinations.
Roberts AR, Appleton LH, Cortes A, **Vecellio M**, Lau J, Watts L, Brown MA, Wordsworth P.
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):558-561.

8. An ankylosing spondylitis-associated genetic variant in the IL23R-IL12RB2 intergenic region modulates enhancer activity and is associated with increased Th1-cell differentiation.
Roberts AR, **Vecellio M**, Chen L, Ridley A, Cortes A, Knight JC, Bowness P, Cohen CJ, Wordsworth BP.
Ann Rheum Dis. 2016 Dec;75(12):2150-2156.

9. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, Olzscha H, Monteiro O, Martin S, Philpott M, Tumber A, Filippakopoulos P, Yapp C, Wells C, Che KH, Bannister A, Robson S, Kumar U, Parr N, Lee K, Lugo D, Jeffrey P, Taylor S, **Vecellio ML**, Bountra C, Brennan PE, O'Mahony A, Velichko S, Müller S, Hay D, Daniels DL, Urh M, La Thangue NB, Kouzarides T, Prinjha R, Schwaller J, Knapp S.
Cancer Res. 2015 Dec 1;75(23):5106-5119.

10. The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression.
Vecellio M, Roberts AR, Cohen CJ, Cortes A, Knight JC, Bowness P, Wordsworth BP.
Ann Rheum Dis. 2016 Aug;75(8):1534-40.

11. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
Hammitzsch A, Tallant C, Fedorov O, O'Mahony A, Brennan PE, Hay DA, Martinez FO, Al-Mossawi MH, de Wit J, **Vecellio M**, Wells C, Wordsworth P, Müller S, Knapp S, Bowness P.
Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10768-73.

12. The histone acetylase activator pentadecylidenemalonate 1b rescues proliferation and differentiation in the human cardiac mesenchymal cells of type 2 diabetic patients.
Vecellio M, Spallotta F, Nanni S, Colussi C, Cencioni C, Derlet A, Bassetti B, Tilenni M, Carena MC, Farsetti A, Sbardella G, Castellano S, Mai A, Martelli F, Pompilio G, Capogrossi MC, Rossini A, Dimmeler S, Zeiher A, Gaetano C.
Diabetes. 2014 Jun;63(6):2132-47.

13. Detrimental effect of class-selective histone deacetylase inhibitors during tissue regeneration following hindlimb ischemia.
Spallotta F, Tardivo S, Nanni S, Rosati JD, Straino S, Mai A, **Vecellio M**, Valente S, Capogrossi MC, Farsetti A, Martone J, Bozzoni I, Pontecorvi A, Gaetano C, Colussi C.
J Biol Chem. 2013 Aug 9;288(32):22915-29.

14. In vitro epigenetic reprogramming of human cardiac mesenchymal stromal cells into functionally competent cardiovascular precursors.
Vecellio M, Meraviglia V, Nanni S, Barbuti A, Scavone A, DiFrancesco D, Farsetti A, Pompilio G, Colombo GI, Capogrossi MC, Gaetano C, Rossini A.
PLoS One. 2012;7(12):e51694.

15. Human chorionic villus mesenchymal stromal cells reveal strong endothelial conversion properties.
Meraviglia V, **Vecellio M**, Grasselli A, Baccarin M, Farsetti A, Capogrossi MC, Pompilio G, Coviello DA, Gaetano C, Di Segni M, Rossini A.
Differentiation. 2012 Jun;83(5):260-70.

16. Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly.
Giannandrea M, Bianchi V, Mignogna ML, Sirri A, Carrabino S, D'Elia E, **Vecellio M**, Russo S, Cogliati F, Larizza L, Ropers HH, Tzschach A, Kalscheuer V, Oehl-Jaschkowitz B, Skinner C, Schwartz CE, Gecz J, Van Esch H, Raynaud M, Chelly J, de Brouwer AP, Toniolo D, D'Adamo P.
Am J Hum Genet. 2010 Feb 12;86(2):185-95.

17. Cognitive impairment in Gdi1-deficient mice is associated with altered synaptic vesicle pools and short-term synaptic plasticity, and can be corrected by appropriate learning training.
Bianchi V, Farisello P, Baldelli P, Meskenaite V, Milanese M, **Vecellio M**, Mühlemann S, Lipp HP, Bonanno G, Benfenati F, Toniolo D, D'Adamo P.
Hum Mol Genet. 2009 Jan 1;18(1):105

Manuscripts in preparation/under review

1. Defining the AS-associated RUNX3 interactome (in preparation)
Vecellio M, Cortes A, Cohen CJ, Knight JC, Fischer R, Bowness P and Wordsworth BP

2. SNP-mediated disruption of c-Myc binding at *RUNX3* enhancer locus is associated with increase susceptibility to ankylosing spondylitis (in preparation)
Cohen CJ, Ellis J, Brown MA, Wordsworth BP and **Vecellio M**

Grants under review

1. A functional investigation of the inducible nitric oxide synthase (NOS2) association with Ankylosing Spondylitis
Ph.D Scholarship submitted to Arthritis Research UK (review in progress)
Matteo Vecellio (Lead Supervisor)